FIELD: medicine.
SUBSTANCE: there are presented pharmaceutical compositions for treating cancer or angiogenesis-related disease and for inhibiting cancer metastasis containing fused protein as an active ingredient, in which the tumor-permeable peptide is fused with an anti-vascular endothelial growth factor (anti-VEGF) agent. Disclosed are use of said fused protein to produce an agent for treating cancer or angiogenesis-related disease and for inhibiting cancer metastasis and methods of treating cancer or angiogenesis-related disease and inhibiting metastasis in a subject in need thereof.
EFFECT: proposed group of inventions provides the effect of targeting cancer, thereby inhibiting angiogenesis and having a therapeutic effect on cancer, demonstrating resistance or immunity to the agent against VEGF.
14 cl, 12 dwg, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS | 2016 |
|
RU2720688C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES, CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TISSUE-PENETRATING PEPTIDE AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED | 2016 |
|
RU2712623C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN | 2018 |
|
RU2813996C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
